Bristol-Myers Squibb Co (WBO:BMYS) LT-Debt-to-Total-Asset : 0.52 (As of Mar. 2024)

View and export this data going back to 2019. Start your Free Trial

What is Bristol-Myers Squibb Co LT-Debt-to-Total-Asset?

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. Bristol-Myers Squibb Co's long-term debt to total assests ratio for the quarter that ended in Mar. 2024 was 0.52.

Bristol-Myers Squibb Co's long-term debt to total assets ratio increased from Mar. 2023 (0.39) to Mar. 2024 (0.52). It may suggest that Bristol-Myers Squibb Co is progressively becoming more dependent on debt to grow their business.

Bristol-Myers Squibb Co LT-Debt-to-Total-Asset Historical Data

The historical data trend for Bristol-Myers Squibb Co's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Bristol-Myers Squibb Co LT-Debt-to-Total-Asset Chart

Bristol-Myers Squibb Co Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

LT-Debt-to-Total-Asset

Get a 7-Day Free Trial

0.34

0.42

0.37

0.38

0.40

Bristol-Myers Squibb Co Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
LT-Debt-to-Total-Asset	Get a 7-Day Free Trial															0.39	0.39	0.37	0.40	0.52

Bristol-Myers Squibb Co LT-Debt-to-Total-Asset Calculation

Bristol-Myers Squibb Co's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Dec. 2023 is calculated as

LT Debt to Total Assets (A: Dec. 2023 )	=	Long-Term Debt & Capital Lease Obligation (A: Dec. 2023 )	/	Total Assets (A: Dec. 2023 )
	=	35013.811	/	87260.803
	=	0.40

Bristol-Myers Squibb Co's Long-Term Debt to Total Asset Ratio for the quarter that ended in Mar. 2024 is calculated as

LT Debt to Total Assets (Q: Mar. 2024 )	=	Long-Term Debt & Capital Lease Obligation (Q: Mar. 2024 )	/	Total Assets (Q: Mar. 2024 )
	=	46966	/	91108.52
	=	0.52

Bristol-Myers Squibb Co (WBO:BMYS) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.

Bristol-Myers Squibb Co LT-Debt-to-Total-Asset Related Terms

Thank you for viewing the detailed overview of Bristol-Myers Squibb Co's LT-Debt-to-Total-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

Bristol-Myers Squibb Co (WBO:BMYS) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Bristol-Myers Squibb Co (WBO:BMYS) » Definitions » LT-Debt-to-Total-Asset

Comparable Companies

Traded in Other Exchanges

BMYMP.PFD:USA BMY:USA BMY:Peru BMY:Mexico 1BMY:Italy BRMd:UK 0R1F:UK BRM:Germany BMYB34:Brazil BMY:Argentina

Address

430 East 29th Street, 14th Floor, New York, NY, USA, 10016

Website

https://www.bms.com

Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Bristol derives close to 70% of total sales from the U.S., showing a higher dependence on the U.S. market than most of its peer group.

Bristol-Myers Squibb Co (WBO:BMYS) Headlines

No Headlines